Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Cervical Cancer and HPV Research, and PARP inhibition in cancer therapy.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Additional file 4 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Additional file 6 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Additional file 5 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Additional file 3 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Additional file 2 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy
Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
A STING-activating nanovaccine for cancer immunotherapy